nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ALB—Crohn's disease	0.167	1	CbGaD
Imatinib—PTGS1—Balsalazide—Crohn's disease	0.11	0.273	CbGbCtD
Imatinib—PTGS1—Mesalazine—Crohn's disease	0.0877	0.218	CbGbCtD
Imatinib—ABCG2—Sulfasalazine—Crohn's disease	0.0531	0.132	CbGbCtD
Imatinib—PTGS1—Sulfasalazine—Crohn's disease	0.049	0.122	CbGbCtD
Imatinib—CYP3A5—Sulfasalazine—Crohn's disease	0.0294	0.0732	CbGbCtD
Imatinib—ALB—Prednisone—Crohn's disease	0.0293	0.0728	CbGbCtD
Imatinib—CYP2C19—Prednisone—Crohn's disease	0.019	0.0472	CbGbCtD
Imatinib—ABCB1—Prednisone—Crohn's disease	0.0153	0.0381	CbGbCtD
Imatinib—KIT—myenteric nerve plexus—Crohn's disease	0.00961	0.0945	CbGeAlD
Imatinib—CYP3A4—Prednisone—Crohn's disease	0.00917	0.0228	CbGbCtD
Imatinib—PDGFRA—penis—Crohn's disease	0.00681	0.0671	CbGeAlD
Imatinib—ORM1—bile—Crohn's disease	0.0061	0.06	CbGeAlD
Imatinib—CA9—gall bladder—Crohn's disease	0.00288	0.0284	CbGeAlD
Imatinib—CA6—mouth—Crohn's disease	0.00283	0.0278	CbGeAlD
Imatinib—CA3—mouth—Crohn's disease	0.00268	0.0264	CbGeAlD
Imatinib—DDR1—smooth muscle tissue—Crohn's disease	0.00255	0.0251	CbGeAlD
Imatinib—ABCA3—mammalian vulva—Crohn's disease	0.00249	0.0245	CbGeAlD
Imatinib—PDGFRA—gall bladder—Crohn's disease	0.00231	0.0228	CbGeAlD
Imatinib—DDR1—mammalian vulva—Crohn's disease	0.00229	0.0226	CbGeAlD
Imatinib—KIT—gall bladder—Crohn's disease	0.00185	0.0182	CbGeAlD
Imatinib—PDGFRB—gall bladder—Crohn's disease	0.0018	0.0178	CbGeAlD
Imatinib—ORM1—gall bladder—Crohn's disease	0.00169	0.0167	CbGeAlD
Imatinib—KIT—mouth—Crohn's disease	0.00164	0.0162	CbGeAlD
Imatinib—ALB—gall bladder—Crohn's disease	0.00148	0.0146	CbGeAlD
Imatinib—PIP4K2C—mammalian vulva—Crohn's disease	0.00142	0.0139	CbGeAlD
Imatinib—CA7—digestive system—Crohn's disease	0.00129	0.0127	CbGeAlD
Imatinib—LCK—mammalian vulva—Crohn's disease	0.00126	0.0124	CbGeAlD
Imatinib—ABCA3—lymph node—Crohn's disease	0.00125	0.0123	CbGeAlD
Imatinib—PDGFRA—smooth muscle tissue—Crohn's disease	0.00115	0.0113	CbGeAlD
Imatinib—DDR1—lymph node—Crohn's disease	0.00115	0.0113	CbGeAlD
Imatinib—CA9—digestive system—Crohn's disease	0.00114	0.0112	CbGeAlD
Imatinib—CA2—gall bladder—Crohn's disease	0.0011	0.0108	CbGeAlD
Imatinib—NQO2—mammalian vulva—Crohn's disease	0.00104	0.0102	CbGeAlD
Imatinib—CSF1R—smooth muscle tissue—Crohn's disease	0.00101	0.00998	CbGeAlD
Imatinib—CSF1R—skin of body—Crohn's disease	0.001	0.00986	CbGeAlD
Imatinib—CA2—mouth—Crohn's disease	0.000974	0.00959	CbGeAlD
Imatinib—KIT—epithelium—Crohn's disease	0.000956	0.00941	CbGeAlD
Imatinib—PDGFRB—epithelium—Crohn's disease	0.000934	0.00919	CbGeAlD
Imatinib—KIT—smooth muscle tissue—Crohn's disease	0.000921	0.00907	CbGeAlD
Imatinib—PDGFRA—lymphoid tissue—Crohn's disease	0.000921	0.00907	CbGeAlD
Imatinib—CSF1R—mammalian vulva—Crohn's disease	0.000913	0.00899	CbGeAlD
Imatinib—PDGFRA—digestive system—Crohn's disease	0.00091	0.00895	CbGeAlD
Imatinib—KIT—skin of body—Crohn's disease	0.000909	0.00895	CbGeAlD
Imatinib—PDGFRB—smooth muscle tissue—Crohn's disease	0.0009	0.00886	CbGeAlD
Imatinib—PDGFRB—skin of body—Crohn's disease	0.000888	0.00874	CbGeAlD
Imatinib—SLC22A2—digestive system—Crohn's disease	0.000864	0.0085	CbGeAlD
Imatinib—CA12—digestive system—Crohn's disease	0.00084	0.00826	CbGeAlD
Imatinib—SLC47A1—mammalian vulva—Crohn's disease	0.000834	0.00821	CbGeAlD
Imatinib—KIT—mammalian vulva—Crohn's disease	0.000829	0.00816	CbGeAlD
Imatinib—CSF1R—lymphoid tissue—Crohn's disease	0.000811	0.00798	CbGeAlD
Imatinib—PDGFRB—mammalian vulva—Crohn's disease	0.00081	0.00797	CbGeAlD
Imatinib—ABL1—smooth muscle tissue—Crohn's disease	0.000802	0.00789	CbGeAlD
Imatinib—CSF1R—digestive system—Crohn's disease	0.000801	0.00788	CbGeAlD
Imatinib—ABL1—skin of body—Crohn's disease	0.000792	0.00779	CbGeAlD
Imatinib—ABL2—lymph node—Crohn's disease	0.00075	0.00738	CbGeAlD
Imatinib—KIT—lymphoid tissue—Crohn's disease	0.000736	0.00725	CbGeAlD
Imatinib—SLC47A1—digestive system—Crohn's disease	0.000732	0.0072	CbGeAlD
Imatinib—KIT—digestive system—Crohn's disease	0.000727	0.00716	CbGeAlD
Imatinib—ABL1—mammalian vulva—Crohn's disease	0.000722	0.00711	CbGeAlD
Imatinib—PDGFRB—lymphoid tissue—Crohn's disease	0.000719	0.00708	CbGeAlD
Imatinib—PDGFRB—digestive system—Crohn's disease	0.00071	0.00699	CbGeAlD
Imatinib—PIP4K2C—lymph node—Crohn's disease	0.000709	0.00698	CbGeAlD
Imatinib—CA3—lymph node—Crohn's disease	0.000677	0.00667	CbGeAlD
Imatinib—CA1—lymphoid tissue—Crohn's disease	0.000673	0.00663	CbGeAlD
Imatinib—CA1—digestive system—Crohn's disease	0.000665	0.00655	CbGeAlD
Imatinib—ABL1—lymphoid tissue—Crohn's disease	0.000641	0.00631	CbGeAlD
Imatinib—ABL1—digestive system—Crohn's disease	0.000633	0.00623	CbGeAlD
Imatinib—LCK—lymph node—Crohn's disease	0.00063	0.0062	CbGeAlD
Imatinib—CA2—epithelium—Crohn's disease	0.000567	0.00558	CbGeAlD
Imatinib—CA2—smooth muscle tissue—Crohn's disease	0.000546	0.00537	CbGeAlD
Imatinib—CA2—skin of body—Crohn's disease	0.000539	0.0053	CbGeAlD
Imatinib—NQO2—lymph node—Crohn's disease	0.000521	0.00513	CbGeAlD
Imatinib—PDGFRA—lymph node—Crohn's disease	0.00052	0.00511	CbGeAlD
Imatinib—CA2—mammalian vulva—Crohn's disease	0.000492	0.00484	CbGeAlD
Imatinib—CYP2C19—digestive system—Crohn's disease	0.00047	0.00463	CbGeAlD
Imatinib—CSF1R—lymph node—Crohn's disease	0.000458	0.0045	CbGeAlD
Imatinib—ABCG2—mammalian vulva—Crohn's disease	0.000455	0.00448	CbGeAlD
Imatinib—PTGS1—epithelium—Crohn's disease	0.000438	0.00431	CbGeAlD
Imatinib—CA2—lymphoid tissue—Crohn's disease	0.000436	0.0043	CbGeAlD
Imatinib—CA2—digestive system—Crohn's disease	0.000431	0.00424	CbGeAlD
Imatinib—PTGS1—smooth muscle tissue—Crohn's disease	0.000422	0.00415	CbGeAlD
Imatinib—SLC47A1—lymph node—Crohn's disease	0.000418	0.00411	CbGeAlD
Imatinib—PTGS1—skin of body—Crohn's disease	0.000416	0.0041	CbGeAlD
Imatinib—KIT—lymph node—Crohn's disease	0.000415	0.00409	CbGeAlD
Imatinib—PDGFRB—lymph node—Crohn's disease	0.000406	0.00399	CbGeAlD
Imatinib—CYP1A2—digestive system—Crohn's disease	0.000384	0.00378	CbGeAlD
Imatinib—ORM1—lymph node—Crohn's disease	0.000381	0.00375	CbGeAlD
Imatinib—CA1—lymph node—Crohn's disease	0.00038	0.00374	CbGeAlD
Imatinib—PTGS1—mammalian vulva—Crohn's disease	0.00038	0.00374	CbGeAlD
Imatinib—Pancreatitis—Mesalazine—Crohn's disease	0.000373	0.00184	CcSEcCtD
Imatinib—Infestation—Azathioprine—Crohn's disease	0.000373	0.00183	CcSEcCtD
Imatinib—Infestation NOS—Azathioprine—Crohn's disease	0.000373	0.00183	CcSEcCtD
Imatinib—Angina pectoris—Mesalazine—Crohn's disease	0.000371	0.00182	CcSEcCtD
Imatinib—CYP3A5—digestive system—Crohn's disease	0.000371	0.00365	CbGeAlD
Imatinib—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00037	0.00182	CcSEcCtD
Imatinib—Contusion—Prednisone—Crohn's disease	0.000368	0.00181	CcSEcCtD
Imatinib—CYP2C9—digestive system—Crohn's disease	0.000365	0.00359	CbGeAlD
Imatinib—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000364	0.00179	CcSEcCtD
Imatinib—Pancytopenia—Mesalazine—Crohn's disease	0.000362	0.00178	CcSEcCtD
Imatinib—ABL1—lymph node—Crohn's disease	0.000362	0.00356	CbGeAlD
Imatinib—Neutropenia—Mesalazine—Crohn's disease	0.000356	0.00175	CcSEcCtD
Imatinib—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000354	0.00174	CcSEcCtD
Imatinib—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000353	0.00173	CcSEcCtD
Imatinib—Pollakiuria—Mesalazine—Crohn's disease	0.000352	0.00173	CcSEcCtD
Imatinib—Agranulocytosis—Azathioprine—Crohn's disease	0.000348	0.00171	CcSEcCtD
Imatinib—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000348	0.00171	CcSEcCtD
Imatinib—Decreased appetite—Mercaptopurine—Crohn's disease	0.000347	0.00171	CcSEcCtD
Imatinib—Weight increased—Mesalazine—Crohn's disease	0.000347	0.0017	CcSEcCtD
Imatinib—Weight decreased—Mesalazine—Crohn's disease	0.000345	0.00169	CcSEcCtD
Imatinib—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000345	0.00169	CcSEcCtD
Imatinib—Pneumonia—Mesalazine—Crohn's disease	0.000342	0.00168	CcSEcCtD
Imatinib—Infestation NOS—Mesalazine—Crohn's disease	0.00034	0.00167	CcSEcCtD
Imatinib—Infestation—Mesalazine—Crohn's disease	0.00034	0.00167	CcSEcCtD
Imatinib—Ulcer—Prednisone—Crohn's disease	0.00034	0.00167	CcSEcCtD
Imatinib—Depression—Mesalazine—Crohn's disease	0.000339	0.00167	CcSEcCtD
Imatinib—Cataract—Prednisone—Crohn's disease	0.000337	0.00166	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.000337	0.00166	CcSEcCtD
Imatinib—Haemoglobin—Azathioprine—Crohn's disease	0.000336	0.00165	CcSEcCtD
Imatinib—Haemorrhage—Azathioprine—Crohn's disease	0.000335	0.00165	CcSEcCtD
Imatinib—Renal failure—Mesalazine—Crohn's disease	0.000334	0.00164	CcSEcCtD
Imatinib—ALB—lymph node—Crohn's disease	0.000334	0.00328	CbGeAlD
Imatinib—PTGS1—digestive system—Crohn's disease	0.000333	0.00328	CbGeAlD
Imatinib—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000333	0.00164	CcSEcCtD
Imatinib—Stomatitis—Mesalazine—Crohn's disease	0.000331	0.00163	CcSEcCtD
Imatinib—Jaundice—Mesalazine—Crohn's disease	0.000331	0.00163	CcSEcCtD
Imatinib—Urinary tract infection—Mesalazine—Crohn's disease	0.00033	0.00162	CcSEcCtD
Imatinib—Conjunctivitis—Mesalazine—Crohn's disease	0.00033	0.00162	CcSEcCtD
Imatinib—Vasculitis—Prednisone—Crohn's disease	0.000329	0.00162	CcSEcCtD
Imatinib—Sweating—Mesalazine—Crohn's disease	0.000326	0.0016	CcSEcCtD
Imatinib—Haematuria—Mesalazine—Crohn's disease	0.000324	0.00159	CcSEcCtD
Imatinib—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000321	0.00158	CcSEcCtD
Imatinib—Epistaxis—Mesalazine—Crohn's disease	0.00032	0.00158	CcSEcCtD
Imatinib—Sinusitis—Mesalazine—Crohn's disease	0.000319	0.00157	CcSEcCtD
Imatinib—Agranulocytosis—Mesalazine—Crohn's disease	0.000317	0.00156	CcSEcCtD
Imatinib—Erythema multiforme—Azathioprine—Crohn's disease	0.000316	0.00156	CcSEcCtD
Imatinib—Body temperature increased—Mercaptopurine—Crohn's disease	0.000315	0.00155	CcSEcCtD
Imatinib—Skin exfoliation—Prednisone—Crohn's disease	0.000307	0.00151	CcSEcCtD
Imatinib—Haemoglobin—Mesalazine—Crohn's disease	0.000306	0.00151	CcSEcCtD
Imatinib—Rhinitis—Mesalazine—Crohn's disease	0.000306	0.0015	CcSEcCtD
Imatinib—Fluid retention—Prednisone—Crohn's disease	0.000305	0.0015	CcSEcCtD
Imatinib—Haemorrhage—Mesalazine—Crohn's disease	0.000305	0.0015	CcSEcCtD
Imatinib—Hepatitis—Mesalazine—Crohn's disease	0.000305	0.0015	CcSEcCtD
Imatinib—Pharyngitis—Mesalazine—Crohn's disease	0.000303	0.00149	CcSEcCtD
Imatinib—Immune system disorder—Azathioprine—Crohn's disease	0.000302	0.00149	CcSEcCtD
Imatinib—Mediastinal disorder—Azathioprine—Crohn's disease	0.000302	0.00148	CcSEcCtD
Imatinib—Urinary tract disorder—Mesalazine—Crohn's disease	0.000301	0.00148	CcSEcCtD
Imatinib—Oedema peripheral—Mesalazine—Crohn's disease	0.0003	0.00148	CcSEcCtD
Imatinib—Chills—Azathioprine—Crohn's disease	0.0003	0.00148	CcSEcCtD
Imatinib—Connective tissue disorder—Mesalazine—Crohn's disease	0.0003	0.00147	CcSEcCtD
Imatinib—Arrhythmia—Azathioprine—Crohn's disease	0.000299	0.00147	CcSEcCtD
Imatinib—Urethral disorder—Mesalazine—Crohn's disease	0.000299	0.00147	CcSEcCtD
Imatinib—Alopecia—Azathioprine—Crohn's disease	0.000296	0.00145	CcSEcCtD
Imatinib—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000294	0.00145	CcSEcCtD
Imatinib—Oesophagitis—Prednisone—Crohn's disease	0.000293	0.00144	CcSEcCtD
Imatinib—Ecchymosis—Prednisone—Crohn's disease	0.00029	0.00143	CcSEcCtD
Imatinib—Erythema multiforme—Mesalazine—Crohn's disease	0.000288	0.00142	CcSEcCtD
Imatinib—Pulmonary oedema—Prednisone—Crohn's disease	0.000286	0.00141	CcSEcCtD
Imatinib—Eye disorder—Mesalazine—Crohn's disease	0.000285	0.0014	CcSEcCtD
Imatinib—Tinnitus—Mesalazine—Crohn's disease	0.000284	0.0014	CcSEcCtD
Imatinib—Cardiac disorder—Mesalazine—Crohn's disease	0.000283	0.00139	CcSEcCtD
Imatinib—Sepsis—Prednisone—Crohn's disease	0.000279	0.00137	CcSEcCtD
Imatinib—CYP3A4—digestive system—Crohn's disease	0.000278	0.00274	CbGeAlD
Imatinib—Angiopathy—Mesalazine—Crohn's disease	0.000277	0.00136	CcSEcCtD
Imatinib—Immune system disorder—Mesalazine—Crohn's disease	0.000275	0.00135	CcSEcCtD
Imatinib—Mediastinal disorder—Mesalazine—Crohn's disease	0.000275	0.00135	CcSEcCtD
Imatinib—CYP2D6—digestive system—Crohn's disease	0.000274	0.00269	CbGeAlD
Imatinib—Chills—Mesalazine—Crohn's disease	0.000274	0.00135	CcSEcCtD
Imatinib—Diarrhoea—Mercaptopurine—Crohn's disease	0.000273	0.00134	CcSEcCtD
Imatinib—Ill-defined disorder—Azathioprine—Crohn's disease	0.00027	0.00133	CcSEcCtD
Imatinib—Alopecia—Mesalazine—Crohn's disease	0.000269	0.00132	CcSEcCtD
Imatinib—Anaemia—Azathioprine—Crohn's disease	0.000269	0.00132	CcSEcCtD
Imatinib—Mental disorder—Mesalazine—Crohn's disease	0.000267	0.00131	CcSEcCtD
Imatinib—Erythema—Mesalazine—Crohn's disease	0.000265	0.00131	CcSEcCtD
Imatinib—Malaise—Azathioprine—Crohn's disease	0.000263	0.00129	CcSEcCtD
Imatinib—Flatulence—Mesalazine—Crohn's disease	0.000261	0.00129	CcSEcCtD
Imatinib—Leukopenia—Azathioprine—Crohn's disease	0.000261	0.00128	CcSEcCtD
Imatinib—Vascular purpura—Prednisone—Crohn's disease	0.000261	0.00128	CcSEcCtD
Imatinib—Dysgeusia—Mesalazine—Crohn's disease	0.00026	0.00128	CcSEcCtD
Imatinib—ABCB1—epithelium—Crohn's disease	0.000259	0.00255	CbGeAlD
Imatinib—Cardiac failure congestive—Prednisone—Crohn's disease	0.000257	0.00126	CcSEcCtD
Imatinib—Back pain—Mesalazine—Crohn's disease	0.000257	0.00126	CcSEcCtD
Imatinib—Muscle spasms—Mesalazine—Crohn's disease	0.000255	0.00125	CcSEcCtD
Imatinib—Vomiting—Mercaptopurine—Crohn's disease	0.000254	0.00125	CcSEcCtD
Imatinib—Rash—Mercaptopurine—Crohn's disease	0.000252	0.00124	CcSEcCtD
Imatinib—Dermatitis—Mercaptopurine—Crohn's disease	0.000251	0.00124	CcSEcCtD
Imatinib—Vision blurred—Mesalazine—Crohn's disease	0.00025	0.00123	CcSEcCtD
Imatinib—Tremor—Mesalazine—Crohn's disease	0.000249	0.00122	CcSEcCtD
Imatinib—Increased appetite—Prednisone—Crohn's disease	0.000248	0.00122	CcSEcCtD
Imatinib—Arthralgia—Azathioprine—Crohn's disease	0.000248	0.00122	CcSEcCtD
Imatinib—Myalgia—Azathioprine—Crohn's disease	0.000248	0.00122	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000246	0.00121	CcSEcCtD
Imatinib—CA2—lymph node—Crohn's disease	0.000246	0.00242	CbGeAlD
Imatinib—Ill-defined disorder—Mesalazine—Crohn's disease	0.000246	0.00121	CcSEcCtD
Imatinib—Anaemia—Mesalazine—Crohn's disease	0.000245	0.00121	CcSEcCtD
Imatinib—Discomfort—Azathioprine—Crohn's disease	0.000245	0.00121	CcSEcCtD
Imatinib—Angioedema—Mesalazine—Crohn's disease	0.000242	0.00119	CcSEcCtD
Imatinib—Purpura—Prednisone—Crohn's disease	0.000242	0.00119	CcSEcCtD
Imatinib—Malaise—Mesalazine—Crohn's disease	0.000239	0.00118	CcSEcCtD
Imatinib—Cardiac failure—Prednisone—Crohn's disease	0.000239	0.00117	CcSEcCtD
Imatinib—Vertigo—Mesalazine—Crohn's disease	0.000238	0.00117	CcSEcCtD
Imatinib—Syncope—Mesalazine—Crohn's disease	0.000238	0.00117	CcSEcCtD
Imatinib—Lethargy—Prednisone—Crohn's disease	0.000238	0.00117	CcSEcCtD
Imatinib—Leukopenia—Mesalazine—Crohn's disease	0.000238	0.00117	CcSEcCtD
Imatinib—Nausea—Mercaptopurine—Crohn's disease	0.000237	0.00117	CcSEcCtD
Imatinib—Infection—Azathioprine—Crohn's disease	0.000236	0.00116	CcSEcCtD
Imatinib—Palpitations—Mesalazine—Crohn's disease	0.000235	0.00115	CcSEcCtD
Imatinib—Loss of consciousness—Mesalazine—Crohn's disease	0.000233	0.00115	CcSEcCtD
Imatinib—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.000233	0.00115	CcSEcCtD
Imatinib—Thrombocytopenia—Azathioprine—Crohn's disease	0.000233	0.00114	CcSEcCtD
Imatinib—Cough—Mesalazine—Crohn's disease	0.000232	0.00114	CcSEcCtD
Imatinib—Skin disorder—Azathioprine—Crohn's disease	0.000231	0.00114	CcSEcCtD
Imatinib—Hypertension—Mesalazine—Crohn's disease	0.000229	0.00113	CcSEcCtD
Imatinib—ABCG2—lymph node—Crohn's disease	0.000228	0.00224	CbGeAlD
Imatinib—Chest pain—Mesalazine—Crohn's disease	0.000226	0.00111	CcSEcCtD
Imatinib—Arthralgia—Mesalazine—Crohn's disease	0.000226	0.00111	CcSEcCtD
Imatinib—Myalgia—Mesalazine—Crohn's disease	0.000226	0.00111	CcSEcCtD
Imatinib—Anxiety—Mesalazine—Crohn's disease	0.000225	0.00111	CcSEcCtD
Imatinib—Face oedema—Prednisone—Crohn's disease	0.000225	0.00111	CcSEcCtD
Imatinib—ABCB1—mammalian vulva—Crohn's disease	0.000224	0.00221	CbGeAlD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000224	0.0011	CcSEcCtD
Imatinib—Discomfort—Mesalazine—Crohn's disease	0.000223	0.0011	CcSEcCtD
Imatinib—Hypotension—Azathioprine—Crohn's disease	0.000222	0.00109	CcSEcCtD
Imatinib—Cardiac arrest—Prednisone—Crohn's disease	0.000222	0.00109	CcSEcCtD
Imatinib—Dry mouth—Mesalazine—Crohn's disease	0.000221	0.00109	CcSEcCtD
Imatinib—Confusional state—Mesalazine—Crohn's disease	0.000218	0.00107	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000217	0.00107	CcSEcCtD
Imatinib—Oedema—Mesalazine—Crohn's disease	0.000217	0.00107	CcSEcCtD
Imatinib—Anaphylactic shock—Mesalazine—Crohn's disease	0.000217	0.00107	CcSEcCtD
Imatinib—Infection—Mesalazine—Crohn's disease	0.000215	0.00106	CcSEcCtD
Imatinib—Dry skin—Prednisone—Crohn's disease	0.000214	0.00105	CcSEcCtD
Imatinib—Shock—Mesalazine—Crohn's disease	0.000213	0.00105	CcSEcCtD
Imatinib—Nervous system disorder—Mesalazine—Crohn's disease	0.000212	0.00104	CcSEcCtD
Imatinib—Hypokalaemia—Prednisone—Crohn's disease	0.000212	0.00104	CcSEcCtD
Imatinib—Thrombocytopenia—Mesalazine—Crohn's disease	0.000212	0.00104	CcSEcCtD
Imatinib—Tachycardia—Mesalazine—Crohn's disease	0.000211	0.00104	CcSEcCtD
Imatinib—Skin disorder—Mesalazine—Crohn's disease	0.00021	0.00103	CcSEcCtD
Imatinib—Hyperhidrosis—Mesalazine—Crohn's disease	0.000209	0.00103	CcSEcCtD
Imatinib—Anorexia—Mesalazine—Crohn's disease	0.000206	0.00102	CcSEcCtD
Imatinib—Muscular weakness—Prednisone—Crohn's disease	0.000206	0.00101	CcSEcCtD
Imatinib—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000206	0.00101	CcSEcCtD
Imatinib—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000205	0.00101	CcSEcCtD
Imatinib—Abdominal distension—Prednisone—Crohn's disease	0.000203	0.000998	CcSEcCtD
Imatinib—Hypotension—Mesalazine—Crohn's disease	0.000202	0.000995	CcSEcCtD
Imatinib—ABCB1—lymphoid tissue—Crohn's disease	0.000199	0.00196	CbGeAlD
Imatinib—Pancreatitis—Prednisone—Crohn's disease	0.000198	0.000972	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000197	0.00097	CcSEcCtD
Imatinib—ABCB1—digestive system—Crohn's disease	0.000197	0.00194	CbGeAlD
Imatinib—Sweating increased—Prednisone—Crohn's disease	0.000196	0.000965	CcSEcCtD
Imatinib—Feeling abnormal—Azathioprine—Crohn's disease	0.000196	0.000964	CcSEcCtD
Imatinib—Insomnia—Mesalazine—Crohn's disease	0.000196	0.000963	CcSEcCtD
Imatinib—Paraesthesia—Mesalazine—Crohn's disease	0.000194	0.000956	CcSEcCtD
Imatinib—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000194	0.000956	CcSEcCtD
Imatinib—Dyspnoea—Mesalazine—Crohn's disease	0.000193	0.00095	CcSEcCtD
Imatinib—Somnolence—Mesalazine—Crohn's disease	0.000193	0.000947	CcSEcCtD
Imatinib—Dyspepsia—Mesalazine—Crohn's disease	0.000191	0.000938	CcSEcCtD
Imatinib—PTGS1—lymph node—Crohn's disease	0.00019	0.00187	CbGeAlD
Imatinib—Neutropenia—Prednisone—Crohn's disease	0.000188	0.000927	CcSEcCtD
Imatinib—Decreased appetite—Mesalazine—Crohn's disease	0.000188	0.000926	CcSEcCtD
Imatinib—Body temperature increased—Azathioprine—Crohn's disease	0.000188	0.000924	CcSEcCtD
Imatinib—Abdominal pain—Azathioprine—Crohn's disease	0.000188	0.000924	CcSEcCtD
Imatinib—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000187	0.00092	CcSEcCtD
Imatinib—Fatigue—Mesalazine—Crohn's disease	0.000187	0.000918	CcSEcCtD
Imatinib—Erectile dysfunction—Prednisone—Crohn's disease	0.000186	0.000913	CcSEcCtD
Imatinib—Pain—Mesalazine—Crohn's disease	0.000185	0.000911	CcSEcCtD
Imatinib—Constipation—Mesalazine—Crohn's disease	0.000185	0.000911	CcSEcCtD
Imatinib—Weight increased—Prednisone—Crohn's disease	0.000183	0.000902	CcSEcCtD
Imatinib—Weight decreased—Prednisone—Crohn's disease	0.000182	0.000897	CcSEcCtD
Imatinib—Hyperglycaemia—Prednisone—Crohn's disease	0.000182	0.000894	CcSEcCtD
Imatinib—Depression—Prednisone—Crohn's disease	0.000179	0.000881	CcSEcCtD
Imatinib—Feeling abnormal—Mesalazine—Crohn's disease	0.000178	0.000878	CcSEcCtD
Imatinib—Acute coronary syndrome—Prednisone—Crohn's disease	0.000177	0.000871	CcSEcCtD
Imatinib—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000177	0.000871	CcSEcCtD
Imatinib—Neuropathy peripheral—Prednisone—Crohn's disease	0.000176	0.000866	CcSEcCtD
Imatinib—Myocardial infarction—Prednisone—Crohn's disease	0.000176	0.000866	CcSEcCtD
Imatinib—Hypersensitivity—Azathioprine—Crohn's disease	0.000175	0.000862	CcSEcCtD
Imatinib—Urticaria—Mesalazine—Crohn's disease	0.000172	0.000846	CcSEcCtD
Imatinib—Abdominal pain—Mesalazine—Crohn's disease	0.000171	0.000842	CcSEcCtD
Imatinib—Body temperature increased—Mesalazine—Crohn's disease	0.000171	0.000842	CcSEcCtD
Imatinib—Diarrhoea—Azathioprine—Crohn's disease	0.000163	0.0008	CcSEcCtD
Imatinib—Haemoglobin—Prednisone—Crohn's disease	0.000162	0.000797	CcSEcCtD
Imatinib—Haemorrhage—Prednisone—Crohn's disease	0.000161	0.000793	CcSEcCtD
Imatinib—Hypersensitivity—Mesalazine—Crohn's disease	0.00016	0.000785	CcSEcCtD
Imatinib—Connective tissue disorder—Prednisone—Crohn's disease	0.000158	0.000779	CcSEcCtD
Imatinib—Dizziness—Azathioprine—Crohn's disease	0.000157	0.000773	CcSEcCtD
Imatinib—Asthenia—Mesalazine—Crohn's disease	0.000155	0.000764	CcSEcCtD
Imatinib—Pruritus—Mesalazine—Crohn's disease	0.000153	0.000754	CcSEcCtD
Imatinib—Vomiting—Azathioprine—Crohn's disease	0.000151	0.000743	CcSEcCtD
Imatinib—Eye disorder—Prednisone—Crohn's disease	0.000151	0.000741	CcSEcCtD
Imatinib—Rash—Azathioprine—Crohn's disease	0.00015	0.000737	CcSEcCtD
Imatinib—Dermatitis—Azathioprine—Crohn's disease	0.00015	0.000737	CcSEcCtD
Imatinib—Flushing—Prednisone—Crohn's disease	0.00015	0.000736	CcSEcCtD
Imatinib—Headache—Azathioprine—Crohn's disease	0.000149	0.000733	CcSEcCtD
Imatinib—Diarrhoea—Mesalazine—Crohn's disease	0.000148	0.000729	CcSEcCtD
Imatinib—Angiopathy—Prednisone—Crohn's disease	0.000146	0.00072	CcSEcCtD
Imatinib—Immune system disorder—Prednisone—Crohn's disease	0.000146	0.000716	CcSEcCtD
Imatinib—Arrhythmia—Prednisone—Crohn's disease	0.000144	0.000709	CcSEcCtD
Imatinib—Dizziness—Mesalazine—Crohn's disease	0.000143	0.000704	CcSEcCtD
Imatinib—Alopecia—Prednisone—Crohn's disease	0.000143	0.000701	CcSEcCtD
Imatinib—Mental disorder—Prednisone—Crohn's disease	0.000141	0.000695	CcSEcCtD
Imatinib—Nausea—Azathioprine—Crohn's disease	0.000141	0.000695	CcSEcCtD
Imatinib—Malnutrition—Prednisone—Crohn's disease	0.00014	0.00069	CcSEcCtD
Imatinib—Erythema—Prednisone—Crohn's disease	0.00014	0.00069	CcSEcCtD
Imatinib—Vomiting—Mesalazine—Crohn's disease	0.000138	0.000677	CcSEcCtD
Imatinib—Rash—Mesalazine—Crohn's disease	0.000137	0.000672	CcSEcCtD
Imatinib—Dermatitis—Mesalazine—Crohn's disease	0.000136	0.000671	CcSEcCtD
Imatinib—Headache—Mesalazine—Crohn's disease	0.000136	0.000667	CcSEcCtD
Imatinib—Vision blurred—Prednisone—Crohn's disease	0.000132	0.000651	CcSEcCtD
Imatinib—Ill-defined disorder—Prednisone—Crohn's disease	0.00013	0.000641	CcSEcCtD
Imatinib—Anaemia—Prednisone—Crohn's disease	0.00013	0.000638	CcSEcCtD
Imatinib—Nausea—Mesalazine—Crohn's disease	0.000129	0.000633	CcSEcCtD
Imatinib—Angioedema—Prednisone—Crohn's disease	0.000128	0.000631	CcSEcCtD
Imatinib—Malaise—Prednisone—Crohn's disease	0.000127	0.000623	CcSEcCtD
Imatinib—Vertigo—Prednisone—Crohn's disease	0.000126	0.00062	CcSEcCtD
Imatinib—Syncope—Prednisone—Crohn's disease	0.000126	0.000619	CcSEcCtD
Imatinib—Loss of consciousness—Prednisone—Crohn's disease	0.000123	0.000607	CcSEcCtD
Imatinib—Convulsion—Prednisone—Crohn's disease	0.000122	0.000598	CcSEcCtD
Imatinib—Hypertension—Prednisone—Crohn's disease	0.000121	0.000596	CcSEcCtD
Imatinib—Arthralgia—Prednisone—Crohn's disease	0.00012	0.000588	CcSEcCtD
Imatinib—Myalgia—Prednisone—Crohn's disease	0.00012	0.000588	CcSEcCtD
Imatinib—Anxiety—Prednisone—Crohn's disease	0.000119	0.000586	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000119	0.000584	CcSEcCtD
Imatinib—Discomfort—Prednisone—Crohn's disease	0.000118	0.000581	CcSEcCtD
Imatinib—Anaphylactic shock—Prednisone—Crohn's disease	0.000115	0.000564	CcSEcCtD
Imatinib—Oedema—Prednisone—Crohn's disease	0.000115	0.000564	CcSEcCtD
Imatinib—Infection—Prednisone—Crohn's disease	0.000114	0.00056	CcSEcCtD
Imatinib—Shock—Prednisone—Crohn's disease	0.000113	0.000554	CcSEcCtD
Imatinib—ABCB1—lymph node—Crohn's disease	0.000112	0.00111	CbGeAlD
Imatinib—Nervous system disorder—Prednisone—Crohn's disease	0.000112	0.000553	CcSEcCtD
Imatinib—Tachycardia—Prednisone—Crohn's disease	0.000112	0.00055	CcSEcCtD
Imatinib—Skin disorder—Prednisone—Crohn's disease	0.000111	0.000547	CcSEcCtD
Imatinib—Hyperhidrosis—Prednisone—Crohn's disease	0.000111	0.000545	CcSEcCtD
Imatinib—Anorexia—Prednisone—Crohn's disease	0.000109	0.000537	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000104	0.000513	CcSEcCtD
Imatinib—Insomnia—Prednisone—Crohn's disease	0.000104	0.00051	CcSEcCtD
Imatinib—Paraesthesia—Prednisone—Crohn's disease	0.000103	0.000506	CcSEcCtD
Imatinib—Dyspepsia—Prednisone—Crohn's disease	0.000101	0.000496	CcSEcCtD
Imatinib—Decreased appetite—Prednisone—Crohn's disease	9.96e-05	0.00049	CcSEcCtD
Imatinib—Fatigue—Prednisone—Crohn's disease	9.88e-05	0.000486	CcSEcCtD
Imatinib—Constipation—Prednisone—Crohn's disease	9.8e-05	0.000482	CcSEcCtD
Imatinib—Feeling abnormal—Prednisone—Crohn's disease	9.44e-05	0.000464	CcSEcCtD
Imatinib—Gastrointestinal pain—Prednisone—Crohn's disease	9.37e-05	0.000461	CcSEcCtD
Imatinib—Urticaria—Prednisone—Crohn's disease	9.1e-05	0.000448	CcSEcCtD
Imatinib—Abdominal pain—Prednisone—Crohn's disease	9.06e-05	0.000445	CcSEcCtD
Imatinib—Body temperature increased—Prednisone—Crohn's disease	9.06e-05	0.000445	CcSEcCtD
Imatinib—Hypersensitivity—Prednisone—Crohn's disease	8.44e-05	0.000415	CcSEcCtD
Imatinib—Asthenia—Prednisone—Crohn's disease	8.22e-05	0.000404	CcSEcCtD
Imatinib—Pruritus—Prednisone—Crohn's disease	8.11e-05	0.000399	CcSEcCtD
Imatinib—Diarrhoea—Prednisone—Crohn's disease	7.84e-05	0.000386	CcSEcCtD
Imatinib—Dizziness—Prednisone—Crohn's disease	7.58e-05	0.000373	CcSEcCtD
Imatinib—Vomiting—Prednisone—Crohn's disease	7.29e-05	0.000358	CcSEcCtD
Imatinib—Rash—Prednisone—Crohn's disease	7.22e-05	0.000355	CcSEcCtD
Imatinib—Dermatitis—Prednisone—Crohn's disease	7.22e-05	0.000355	CcSEcCtD
Imatinib—Headache—Prednisone—Crohn's disease	7.18e-05	0.000353	CcSEcCtD
Imatinib—Nausea—Prednisone—Crohn's disease	6.81e-05	0.000335	CcSEcCtD
Imatinib—LCK—Disease—UBE2D1—Crohn's disease	1.69e-05	0.000134	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—SMAD3—Crohn's disease	1.69e-05	0.000133	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RBX1—Crohn's disease	1.69e-05	0.000133	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL2RA—Crohn's disease	1.68e-05	0.000133	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—RIPK2—Crohn's disease	1.68e-05	0.000133	CbGpPWpGaD
Imatinib—LCK—Immune System—RASGRP1—Crohn's disease	1.68e-05	0.000132	CbGpPWpGaD
Imatinib—PDGFRA—Disease—SMAD3—Crohn's disease	1.68e-05	0.000132	CbGpPWpGaD
Imatinib—LCK—Hemostasis—ALB—Crohn's disease	1.68e-05	0.000132	CbGpPWpGaD
Imatinib—KIT—Immune System—CRP—Crohn's disease	1.67e-05	0.000132	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	1.67e-05	0.000132	CbGpPWpGaD
Imatinib—LCK—Immune System—CD79A—Crohn's disease	1.67e-05	0.000132	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL18—Crohn's disease	1.66e-05	0.000131	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—CD4—Crohn's disease	1.66e-05	0.000131	CbGpPWpGaD
Imatinib—LCK—Immune System—TAB1—Crohn's disease	1.64e-05	0.000129	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTGER4—Crohn's disease	1.64e-05	0.000129	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—UBE2D1—Crohn's disease	1.64e-05	0.000129	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	1.64e-05	0.000129	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL3—Crohn's disease	1.64e-05	0.000129	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—FADS1—Crohn's disease	1.64e-05	0.000129	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTMR3—Crohn's disease	1.63e-05	0.000128	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CD4—Crohn's disease	1.61e-05	0.000127	CbGpPWpGaD
Imatinib—LCK—Immune System—NOD2—Crohn's disease	1.61e-05	0.000127	CbGpPWpGaD
Imatinib—KIT—Immune System—TLR4—Crohn's disease	1.61e-05	0.000127	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—RIPK2—Crohn's disease	1.59e-05	0.000125	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD4—Crohn's disease	1.59e-05	0.000125	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTMR3—Crohn's disease	1.59e-05	0.000125	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CRP—Crohn's disease	1.59e-05	0.000125	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—RASGRP1—Crohn's disease	1.58e-05	0.000125	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—IL6—Crohn's disease	1.57e-05	0.000124	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL2RA—Crohn's disease	1.57e-05	0.000124	CbGpPWpGaD
Imatinib—LCK—Hemostasis—JAK2—Crohn's disease	1.56e-05	0.000123	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL3—Crohn's disease	1.55e-05	0.000122	CbGpPWpGaD
Imatinib—CA2—Metabolism—ALB—Crohn's disease	1.54e-05	0.000122	CbGpPWpGaD
Imatinib—KIT—Immune System—ICAM1—Crohn's disease	1.54e-05	0.000121	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GPX4—Crohn's disease	1.53e-05	0.000121	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—TLR4—Crohn's disease	1.52e-05	0.00012	CbGpPWpGaD
Imatinib—LCK—Immune System—SOCS1—Crohn's disease	1.52e-05	0.00012	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL2RA—Crohn's disease	1.51e-05	0.000119	CbGpPWpGaD
Imatinib—PDGFRB—Disease—SMAD3—Crohn's disease	1.51e-05	0.000119	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—RASGRP1—Crohn's disease	1.5e-05	0.000118	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCR6—Crohn's disease	1.5e-05	0.000118	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTMR3—Crohn's disease	1.5e-05	0.000118	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	1.49e-05	0.000117	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTMR3—Crohn's disease	1.48e-05	0.000117	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GCKR—Crohn's disease	1.48e-05	0.000117	CbGpPWpGaD
Imatinib—CA1—Metabolism—ALB—Crohn's disease	1.48e-05	0.000117	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—UBE2D1—Crohn's disease	1.48e-05	0.000117	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL2RA—Crohn's disease	1.48e-05	0.000116	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—TYK2—Crohn's disease	1.47e-05	0.000116	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—ICAM1—Crohn's disease	1.46e-05	0.000115	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SOCS1—Crohn's disease	1.44e-05	0.000113	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RIPK2—Crohn's disease	1.43e-05	0.000113	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CRP—Crohn's disease	1.43e-05	0.000113	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.42e-05	0.000112	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—STAT3—Crohn's disease	1.42e-05	0.000112	CbGpPWpGaD
Imatinib—ALB—Metabolism—FADS1—Crohn's disease	1.41e-05	0.000111	CbGpPWpGaD
Imatinib—ABCG2—Transmembrane transport of small molecules—ALB—Crohn's disease	1.4e-05	0.000111	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—JAK2—Crohn's disease	1.4e-05	0.000111	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL3—Crohn's disease	1.4e-05	0.00011	CbGpPWpGaD
Imatinib—ABL1—Immune System—CRP—Crohn's disease	1.39e-05	0.00011	CbGpPWpGaD
Imatinib—SLC22A2—Transmembrane transport of small molecules—ALB—Crohn's disease	1.39e-05	0.00011	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IL2RA—Crohn's disease	1.39e-05	0.000109	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—IL6—Crohn's disease	1.39e-05	0.000109	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—TLR4—Crohn's disease	1.37e-05	0.000108	CbGpPWpGaD
Imatinib—LCK—Immune System—IL18—Crohn's disease	1.37e-05	0.000108	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SOCS1—Crohn's disease	1.36e-05	0.000107	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RBX1—Crohn's disease	1.35e-05	0.000107	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RASGRP1—Crohn's disease	1.35e-05	0.000107	CbGpPWpGaD
Imatinib—CA2—Metabolism—PTGS2—Crohn's disease	1.35e-05	0.000107	CbGpPWpGaD
Imatinib—ABL1—Immune System—TLR4—Crohn's disease	1.33e-05	0.000105	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CD4—Crohn's disease	1.33e-05	0.000105	CbGpPWpGaD
Imatinib—ALB—Metabolism—GPX4—Crohn's disease	1.32e-05	0.000104	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTGER4—Crohn's disease	1.32e-05	0.000104	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—ICAM1—Crohn's disease	1.31e-05	0.000104	CbGpPWpGaD
Imatinib—CA9—Metabolism—ALB—Crohn's disease	1.3e-05	0.000103	CbGpPWpGaD
Imatinib—SLC22A1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.3e-05	0.000102	CbGpPWpGaD
Imatinib—CA1—Metabolism—PTGS2—Crohn's disease	1.3e-05	0.000102	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL6—Crohn's disease	1.28e-05	0.000101	CbGpPWpGaD
Imatinib—ABL1—Immune System—ICAM1—Crohn's disease	1.28e-05	0.000101	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD4—Crohn's disease	1.28e-05	0.000101	CbGpPWpGaD
Imatinib—ALB—Metabolism—GCKR—Crohn's disease	1.28e-05	0.000101	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTMR3—Crohn's disease	1.27e-05	9.99e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—FADS1—Crohn's disease	1.27e-05	9.99e-05	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—IL6—Crohn's disease	1.26e-05	9.94e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—TYK2—Crohn's disease	1.25e-05	9.87e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.24e-05	9.8e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SMAD3—Crohn's disease	1.24e-05	9.78e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—FADS1—Crohn's disease	1.24e-05	9.75e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TNF—Crohn's disease	1.22e-05	9.66e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SOCS1—Crohn's disease	1.22e-05	9.66e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2RA—Crohn's disease	1.22e-05	9.58e-05	CbGpPWpGaD
Imatinib—LCK—Disease—SMAD3—Crohn's disease	1.21e-05	9.56e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—JAK2—Crohn's disease	1.19e-05	9.41e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—UBE2D1—Crohn's disease	1.19e-05	9.35e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GPX4—Crohn's disease	1.19e-05	9.35e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—TYK2—Crohn's disease	1.18e-05	9.34e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SMAD3—Crohn's disease	1.17e-05	9.26e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IFNG—Crohn's disease	1.17e-05	9.24e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—FADS1—Crohn's disease	1.16e-05	9.19e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GPX4—Crohn's disease	1.16e-05	9.13e-05	CbGpPWpGaD
Imatinib—KIT—Disease—TYK2—Crohn's disease	1.15e-05	9.11e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—FADS1—Crohn's disease	1.15e-05	9.11e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RIPK2—Crohn's disease	1.15e-05	9.07e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	1.15e-05	9.07e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2RA—Crohn's disease	1.15e-05	9.05e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CRP—Crohn's disease	1.15e-05	9.04e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GCKR—Crohn's disease	1.15e-05	9.03e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—PTGS2—Crohn's disease	1.14e-05	8.99e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—CD4—Crohn's disease	1.13e-05	8.92e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	1.13e-05	8.91e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—JAK2—Crohn's disease	1.13e-05	8.91e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL3—Crohn's disease	1.12e-05	8.85e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GCKR—Crohn's disease	1.12e-05	8.82e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IFNG—Crohn's disease	1.11e-05	8.75e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TYK2—Crohn's disease	1.1e-05	8.71e-05	CbGpPWpGaD
Imatinib—KIT—Disease—JAK2—Crohn's disease	1.1e-05	8.69e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—TLR4—Crohn's disease	1.1e-05	8.67e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TYK2—Crohn's disease	1.09e-05	8.62e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GPX4—Crohn's disease	1.09e-05	8.6e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2RA—Crohn's disease	1.09e-05	8.57e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RASGRP1—Crohn's disease	1.08e-05	8.56e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GPX4—Crohn's disease	1.08e-05	8.53e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD4—Crohn's disease	1.07e-05	8.45e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—TYK2—Crohn's disease	1.07e-05	8.41e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SMAD3—Crohn's disease	1.06e-05	8.34e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—ICAM1—Crohn's disease	1.05e-05	8.31e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GCKR—Crohn's disease	1.05e-05	8.31e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—JAK2—Crohn's disease	1.05e-05	8.31e-05	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—IL6—Crohn's disease	1.05e-05	8.29e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL1B—Crohn's disease	1.04e-05	8.24e-05	CbGpPWpGaD
Imatinib—KIT—Disease—CD4—Crohn's disease	1.04e-05	8.24e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GCKR—Crohn's disease	1.04e-05	8.24e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—JAK2—Crohn's disease	1.04e-05	8.23e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—TYK2—Crohn's disease	1.04e-05	8.2e-05	CbGpPWpGaD
Imatinib—KIT—Disease—PTGS2—Crohn's disease	1.04e-05	8.18e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—JAK2—Crohn's disease	1.02e-05	8.03e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IFNG—Crohn's disease	9.99e-06	7.88e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—IL6—Crohn's disease	9.94e-06	7.84e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—JAK2—Crohn's disease	9.92e-06	7.82e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL1B—Crohn's disease	9.89e-06	7.8e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CD4—Crohn's disease	9.89e-06	7.8e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—IL6—Crohn's disease	9.89e-06	7.8e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—FADS1—Crohn's disease	9.87e-06	7.78e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TYK2—Crohn's disease	9.85e-06	7.77e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SOCS1—Crohn's disease	9.83e-06	7.75e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PTGS2—Crohn's disease	9.82e-06	7.74e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2RA—Crohn's disease	9.79e-06	7.72e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTMR3—Crohn's disease	9.78e-06	7.71e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IFNG—Crohn's disease	9.74e-06	7.68e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD4—Crohn's disease	9.65e-06	7.61e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CXCL8—Crohn's disease	9.61e-06	7.58e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD4—Crohn's disease	9.4e-06	7.42e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—JAK2—Crohn's disease	9.4e-06	7.41e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—JAK2—Crohn's disease	9.31e-06	7.34e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GPX4—Crohn's disease	9.24e-06	7.29e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—IL6—Crohn's disease	8.96e-06	7.07e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GCKR—Crohn's disease	8.92e-06	7.04e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL1B—Crohn's disease	8.91e-06	7.03e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CD4—Crohn's disease	8.91e-06	7.03e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PTGS2—Crohn's disease	8.84e-06	6.97e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—STAT3—Crohn's disease	8.76e-06	6.91e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—IL6—Crohn's disease	8.73e-06	6.89e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL1B—Crohn's disease	8.68e-06	6.85e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—TYK2—Crohn's disease	8.56e-06	6.75e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SMAD3—Crohn's disease	8.48e-06	6.69e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—STAT3—Crohn's disease	8.29e-06	6.54e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	8.18e-06	6.46e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—JAK2—Crohn's disease	8.17e-06	6.44e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TYK2—Crohn's disease	8.09e-06	6.38e-05	CbGpPWpGaD
Imatinib—KIT—Disease—STAT3—Crohn's disease	8.09e-06	6.38e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IFNG—Crohn's disease	8.02e-06	6.32e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	7.98e-06	6.29e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TYK2—Crohn's disease	7.9e-06	6.23e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2RA—Crohn's disease	7.86e-06	6.2e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CD4—Crohn's disease	7.74e-06	6.11e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—STAT3—Crohn's disease	7.73e-06	6.1e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—JAK2—Crohn's disease	7.72e-06	6.09e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TYK2—Crohn's disease	7.66e-06	6.04e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—STAT3—Crohn's disease	7.66e-06	6.04e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—FADS1—Crohn's disease	7.62e-06	6.01e-05	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	7.6e-06	5.99e-05	CbGpPWpGaD
Imatinib—LCK—Disease—JAK2—Crohn's disease	7.54e-06	5.95e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—STAT3—Crohn's disease	7.47e-06	5.89e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	7.46e-06	5.89e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—JAK2—Crohn's disease	7.3e-06	5.76e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—STAT3—Crohn's disease	7.28e-06	5.74e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—IL6—Crohn's disease	7.19e-06	5.67e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	7.16e-06	5.65e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1B—Crohn's disease	7.15e-06	5.64e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CD4—Crohn's disease	7.15e-06	5.64e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GPX4—Crohn's disease	7.13e-06	5.62e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTGS2—Crohn's disease	7.1e-06	5.6e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCL8—Crohn's disease	7.04e-06	5.55e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TYK2—Crohn's disease	6.9e-06	5.44e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—STAT3—Crohn's disease	6.9e-06	5.44e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GCKR—Crohn's disease	6.89e-06	5.43e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCL8—Crohn's disease	6.67e-06	5.26e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ALB—Crohn's disease	6.58e-06	5.19e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—JAK2—Crohn's disease	6.58e-06	5.19e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	6.53e-06	5.15e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ALB—Crohn's disease	6.52e-06	5.14e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ALB—Crohn's disease	6.51e-06	5.14e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	6.38e-06	5.03e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ALB—Crohn's disease	6.32e-06	4.99e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—Crohn's disease	6.12e-06	4.83e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ALB—Crohn's disease	6.07e-06	4.79e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL8—Crohn's disease	6.01e-06	4.74e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—Crohn's disease	5.99e-06	4.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—Crohn's disease	5.79e-06	4.57e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—Crohn's disease	5.76e-06	4.54e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—Crohn's disease	5.71e-06	4.5e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—Crohn's disease	5.7e-06	4.49e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—Crohn's disease	5.66e-06	4.47e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—Crohn's disease	5.65e-06	4.46e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	5.58e-06	4.4e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TYK2—Crohn's disease	5.54e-06	4.37e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—Crohn's disease	5.53e-06	4.37e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—Crohn's disease	5.53e-06	4.36e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—Crohn's disease	5.4e-06	4.26e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—Crohn's disease	5.36e-06	4.23e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—Crohn's disease	5.35e-06	4.22e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—Crohn's disease	5.31e-06	4.19e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—JAK2—Crohn's disease	5.28e-06	4.17e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—Crohn's disease	5.22e-06	4.12e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—Crohn's disease	5.08e-06	4.01e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—Crohn's disease	4.83e-06	3.81e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—Crohn's disease	4.82e-06	3.8e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—Crohn's disease	4.82e-06	3.8e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—Crohn's disease	4.71e-06	3.72e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—Crohn's disease	4.19e-06	3.3e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—Crohn's disease	4.12e-06	3.25e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—Crohn's disease	3.96e-06	3.12e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—Crohn's disease	3.88e-06	3.06e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—Crohn's disease	3.87e-06	3.05e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—Crohn's disease	3.74e-06	2.95e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—Crohn's disease	3.65e-06	2.88e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—Crohn's disease	3.56e-06	2.81e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—Crohn's disease	3.55e-06	2.8e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—Crohn's disease	3.37e-06	2.66e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—Crohn's disease	3.35e-06	2.64e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—Crohn's disease	3.32e-06	2.62e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—Crohn's disease	3.19e-06	2.52e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—Crohn's disease	3.11e-06	2.46e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—Crohn's disease	2.93e-06	2.31e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—Crohn's disease	2.91e-06	2.29e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—Crohn's disease	2.84e-06	2.24e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—Crohn's disease	2.71e-06	2.14e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—Crohn's disease	2.48e-06	1.96e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—Crohn's disease	2.19e-06	1.73e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—Crohn's disease	1.92e-06	1.51e-05	CbGpPWpGaD
